Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.35 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25435703 | 0.93 | ALDH1A1 (0.36) | ALDH1A1CYP2D6MAPK1LMNACAPN1 | |
| SCHEMBL19492149 | 0.93 | ALDH1A1 (0.36) | ALDH1A1CYP2D6MAPK1LMNACAPN1 | |
| SCHEMBL20394059 | 0.85 | BCHE (0.39) | ALDH1A1CYP2D6MAPK1LMNACAPN1 | |
| SCHEMBL19101763 | 0.82 | LMNA (0.39) | ALDH1A1CYP2D6MAPK1LMNACAPN1 | |
| SCHEMBL26121971 | 0.82 | LMNA (0.39) | ALDH1A1CYP2D6MAPK1LMNACAPN1 | |
| SCHEMBL30590064 | 0.82 | LMNA (0.39) | ALDH1A1CYP2D6MAPK1LMNACAPN1 | |
| SCHEMBL21418923 | 0.82 | ALDH1A1 (0.36) | ALDH1A1CYP2D6MAPK1LMNACAPN1 | |
| SCHEMBL6834854 | 0.82 | ALDH1A1 (0.36) | ALDH1A1CYP2D6MAPK1LMNACAPN1 | |
| SCHEMBL30590044 | 0.82 | ALDH1A1 (0.36) | ALDH1A1CYP2D6MAPK1LMNACAPN1 | |
| SCHEMBL17958889 | 0.82 | ALDH1A1 (0.36) | ALDH1A1CYP2D6MAPK1LMNACAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS INC (US) | 2025-07-03 | — | — | US | disclosed |
| WO-2023192499-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | UNG, OGG1, NTPCR | ALDH1A1 635/4885CYP2D6 1545/4885MAPK1 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.